Capvaxive PCV21
Selected indexed studies
- Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (MMWR Morb Mortal Wkly Rep, 2024) [PMID:39264843]
- Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (MMWR Morb Mortal Wkly Rep, 2025) [PMID:39773952]
- Economic evaluation of PCV21 in PCV-naïve adults aged 50-64 years in the United States. (Vaccine, 2025) [PMID:40412329]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Economic evaluation of PCV21 in PCV-naïve adults aged 50-64 years in the United States. (2025) pubmed
- Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (2024) pubmed
- Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (2025) pubmed
- Anticipated impact of novel adult-specific pneumococcal conjugate vaccine. (2025) pubmed
- What About Vaccine-Experienced Younger Adults? Cost-Effectiveness of PCV21 Use in Vaccine-Experienced US Adults Aged 19-64 Years with Underlying Medical Conditions. (2025) pubmed
- Economic evaluation of PCV21 in vaccine-naïve adults aged 19-64 years with underlying medical conditions in the United States. (2025) pubmed